Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997639 | 0.86 | KDM4E (0.47) | ACACBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL5008474 | 0.85 | NAMPT (0.52) | KDM4EMEN1MAPTKMT2A | |
| Hydrochloric Acid SCHEMBL5012099 | 0.84 | NAMPT (0.51) | KDM4EMEN1MAPTKMT2A | |
| SCHEMBL19051523 | 0.83 | SMN1; SMN2 (0.49) | MAPT | |
| SCHEMBL21900625 | 0.83 | KMT2A (0.44) | ACACBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL24160954 | 0.82 | MTNR1A (0.46) | ACACBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL24943197 | 0.82 | MTNR1A (0.46) | ACACBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL18997712 | 0.82 | MTNR1A (0.46) | ACACBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL19002286 | 0.81 | ACACB (0.51) | ACACBKDM4EMEN1MAPTKMT2A | |
| SCHEMBL19001316 | 0.81 | ACACB (0.48) | ACACBMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2017112777-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ACACB 807/4885KDM4E 3392/4885MEN1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.